my country's biopharmaceutical industry faces development opportunities

Editor:嘉興市舒福特生物科技有限公司 │ Release Time:2020-03-31 

With the continuous improvement of the medical security level of more than 1.3 billion people, my country's biomedical industry has huge market space. Compared with advanced countries in the world, my country's biomedical industry clearly has four major competition gaps. At the second National Bio-Industry Conference held in Changsha a few days ago, authoritative officials, scholars and entrepreneurs who participated in the conference discussed good development plans for the bio-pharmaceutical industry. Development Opportunities.

  my country's biomedicine industry contains huge market space

   At this conference, Canada's world's top biotechnology company Microbix officially signed a contract to invest 1.4 billion yuan to build a flu vaccine base project in Changsha. According to reports, Changsha will become the world's third largest influenza vaccine production base for this project. The construction period of the project is 4 years, and it is expected to be put into production in 2012. The flu vaccine with an annual output of 100 million yuan can meet the domestic needs of China and provide other regions in Asia.

  The hot vaccine industry is a microcosm of the huge market space in the biopharmaceutical industry. The reporter learned from the conference that the vaccine industry with a global market of 10 billion US dollars is one of the most popular in the pharmaceutical industry today. In the past 10 years, China's vaccine market has tripled. A research mechanism predicts that the scale of China's vaccine market will reach 4.36 billion yuan in 2009. It is estimated that the scale of China's vaccine market will be close to 8 billion yuan by 2002.

   The reporter learned from this conference that with the vigorous promotion of the country and the active participation of all sectors of society, such as enterprises and scientific research, since entering the "Eleventh Five-Year" period, my country's biomedical industry has experienced rapid growth, showing a promising development momentum.

Participants believed that the rapid growth of China's vaccine market, on the one hand, benefited from the huge potential of 1.3 billion people bringing China's vaccine market, on the other hand, with the progress of society and the improvement of people's living standards, the transformation of the consumption structure brought People's demand for disease prevention and health care continues to rise. The acceleration of the urbanization process and the advent of an aging society will also bring new demands.

   First, the rapid growth of biomedicine production and sales. According to Wang Jinxiang, deputy director of the National Development and Reform Commission, at the "High-level Forum" of the conference, in 2007, the national biopharmaceutical industry achieved a total industrial output value of 634 billion yuan, an increase of 25.5 percent year-on-year, 5 percentage points higher than the growth rate of the high-tech industry.

   The second is the rapid development of the bio-industry base, showing an attitude towards the development of industrial agglomeration. Since 2005, the National Development and Reform Commission has identified 22 national bio-industry bases. At the same time, it strongly supports the construction of base public service conditions, enhances the base's agglomeration capacity, and promotes the combination of industry and regional economic development. Taking Shanghai as an example, a good innovation and entrepreneurial atmosphere composed of six modules including industrial groups, incubation and innovation, education and training, research and development, professional services, and venture capital has been formed with Zhangjiang National Base as the core.